EICHOR
● Active Not Recruiting
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
Condition: Gastric Adenocarcinoma · Esophagus Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Sponsor: UNICANCER
About this study
Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5-fluorouracile (5-FU) in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (28)
| Clinique de l'Europe | Amiens, France | — |
| Hopital Privé Arras Les Bonnettes | Arras, France | — |
| Institut Sainte Catherine | Avignon, France | — |
| Centre Hospitalier de Beauvais | Beauvais, France | — |
| CHU Besançon - Hôpital Jean Minjoz | Besançon, France | — |
| CHU Morvan | Brest, France | — |
| Clinique Pasteur Lanroze | Brest, France | — |
| CH Cholet | Cholet, France | — |
| Centre Jean Perrin | Clermont-Ferrand, France | — |
| CHU d'Estaing | Clermont-Ferrand, France | — |
| Institut Andrée Dutreix - Clinique de Flandre | Coudekerque-Branche, France | — |
| Hôpital Nord-Ouest Villefranche-sur-Saône | Gleizé, France | — |
+ 16 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05476796